Future therapeutic perspectives for tension-type headache.
The therapy for tension-type headache remains insufficient, and recent advances have been scarce. Although tricyclic antidepressants are at the forefront of treatment advances, upcoming agents tentatively modifying central sensitization are promising. Botulinum toxin failed to meet expectations. This article reviews current treatments, emphasizing newer approaches. Much remains to be achieved.
Lenaerts
Marc E
ME
Department of Neurology, Headache Section, Oklahoma University Health Sciences Center, 711 Stanton L. Young Boulevard, #215, Oklahoma City, OK 73104, USA. marc-lenaerts@ouhsc.edu
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D018781:Tension-Type Headache / Q000188:drug therapy*
D018759:Adrenergic Uptake Inhibitors; D000700:Analgesics; D000701:Analgesics, Opioid; D000929:Antidepressive Agents, Tricyclic; D001463:Barbiturates; D017367:Selective Serotonin Reuptake Inhibitors